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Carbonyl iron powder (CIP) has been used as a food additive or mineral supplement.
However, the effects of CIP on iron deficiency anemia (IDA) and its subchronic toxicity have
not been investigated. We found that oral administration of CIP at a dose of 2.96 mg/kg
recovered the hemoglobin concentration of erythrocytes of IDA rats to the normal level
after 8 days. The no observed adverse effect level of CIP in rats was considered to be >
200 mg/kg. The hematological and serum biochemical parameters of the rats did not differ
significantly between the control and treated groups. There were no morphological
changes observed in the organs including liver, kidneys, spleen, testes, stomach and in-
testine. Therefore, CIP might be a safe iron supplement.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Iron deficiency anemia (IDA) attributable to nutritional defi-
ciency and/or blood loss remains the most common, treatable
form of anemia worldwide [1]. World Health Organization
reports indicate that 2 billion people (> 30% of the world’s
population) have anemia, with ~1 billion having IDA [2]. IDA is
one of the most prevalent nutritional problems in the world
today [3]. According to more recent reports, the global preva-
lence of anemia is 47% in children GED < 5 years, 30% inChina University of Scien
).
study.
inistration, Taiwan. Publis
/licenses/by-nc-nd/4.0/).nonpregnant women of childbearing age, and 42% in pregnant
women, while the prevalence of IDA in pregnant women in
developing countries is 35e75% [4]. Iron participates in
numerous biochemical reactions primarily involved in oxygen
transport and storage, adenosine triphosphate production,
DNA synthesis, and electron transport [5,6]. Iron deficiency
may have specific effects on the central nervous system,
either on neurotransmitters, or on cells or myelin, or there
may be a direct effect of anemia that leads to low oxygen
delivery to the brain [7]. IDA in adults can lead to a wide va-
riety of adverse health outcomes, including diminished workce and Technology, 130 Meilong Road, Shanghai 200237, China.
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gastrointestinal disturbances, and Helicobacter pylori infection
[8e12]. IDA in children can result in neurocognitive impair-
ment leading to psychomotor and cognitive abnormalities,
which, if left unchecked, impairs learning [13,14]. IDA during
pregnancy has long been associated with an increased risk of
low birth weight, preterm delivery, perinatal mortality, and
infant and young childmortality as well asmaternalmortality
[15e18].
Oral iron supplementation is a commonly used strategy to
meet the increased requirements of high-risk groups, such as
women of childbearing age [19]. Different generations of iron
supplements have been developed, including organic and
inorganic forms. Ferrous iron salts (ferrous sulfate and ferrous
gluconate) are preferred because of their low cost and high
bioavailability [20]. With regard to the first generation of iron
supplements, ferrous sulfate is generally regarded as toxic to
the gastrointestinal mucosa, resulting in poor compliance and
treatment failure. Also, it has been demonstrated that ferrous
sulfate can increase plasma malondialdehyde, a marker of
lipid peroxidation, supporting the notion that ferrous iron
may aggravate oxidative tissue damage [21]. The International
Nutritional Anemia Consultative Group has reviewed the use
of FeNa-EDTA as a food supplement. This compound is sug-
gested to be the most suitable iron fortifier in developing
countries where programs for the fortification of cereals, le-
gumes, and infant complementary foods are implemented
[22]. The advantage of FeNa-EDTA is that the iron present in
this compound is prevented from interacting with phytates,
which results in 2e3 times better absorption, compared to
that obtainedwhen other iron compounds are used in fortified
diets [22]. FeNa-EDTA is reported in cereal-based and dairy
foods [23,24]. However, a more recent study suggested that
moderate FeNa-EDTA supplementation could improve he-
matological status in pregnant women with anemia [25].
Ferrous bisglycinate is a chelate that is composed of two
molecules of glycine chelating to an atom of ferrous iron by
covalent and coordinate covalent bonds. This particular form
of chelated iron is effective in reversing IDA in adults, ado-
lescents, and young children [26e28].
Carbonyl iron powder (CIP) is a novel material that has
begun to be used as an iron supplement [29]. CIP is elemental
iron with > 98% iron content, whose key physical property is
its fine spherical particle size (5 mm), and it is considerably
smaller than the 10e100 mm of other forms of elemental iron
(e.g., reduced, electrolytic and atomized). Carbonyl iron has
been approved as a mineral in dietary supplements. The US
Food Chemicals Codex provides CIP particle size 95% through
325 mesh standard sieve, and with > 98% pure iron, can be
added to foods [30]. Carbonyl iron was verified as a safe ma-
terial for iron supplementation because its 50% lethal dose
was> 5 g Fe/kg, comparedwith 1.3 g Fe/kgwas for FeNa-EDTA,
2.8 g Fe/kg for ferrous bisglycinate, and 1.1 mg Fe/kg for FeSO4
[31,32]. Carbonyl iron was once used for iron fortification in
whole-grain wheat flour in some cell models, however,
studies on the use of CIP as an iron supplement (usually in
higher doses, without food) in models of IDA are scarce [33].
Therefore, the objective of this study was to investigate
whether CIP could be a possible iron supplement. CIP was
administered to young male rats with IDA to observe itsinfluence on hemoglobin (HGB) and other blood biochemical
characteristics of rats, using ferrous sulfate as a positive
control. In addition, to assess the safety of CIP when utilized
for food fortification or medicinal supplementation on a daily
basis, 90-day subchronic toxicity was also investigated in rats.2. Materials and methods
2.1. Materials
CIP was purchased from International Specialty Products
(Lakewood, WA, USA). Ferroids (sustained-release tablets of
ferrous sulfate and vitamin complex) were produced by
Medtech Xinghua Pharmaceutical Co. Ltd. (Guangzhou,
China). Each tablet contained 525 mg ferrous sulfate, 500 mg
vitamin C, and inactive ingredients, such as starch and
dextrin. The composition of the low-iron diets used to induce
the rat model of anemia were: corn starch, 640 g/kg; egg white
powder, 200 g/kg; soybean oil, 40 g/kg; mineral mixture
without iron, 25 g/kg; vitaminmixture, 12 g/kg; gluten, 30 g/kg;
sodium chloride, 5 g/kg; calcium carbonate, 20 g/kg; DL-
methionine, 3 g/kg; glucose, 25 g/kg. The formula of the
mineral mixture without iron (1 kg) was: Ca(H2PO3)2, 500 g;
NaCl, 104 g; K3C6H5O7$H2O, 220 g; KH2PO4, 94 g; K2SO4, 52 g;
MgO, 24 g; MnCO3, 3.5 g; ZnCO3, 1.6 g; CuCO3, 300 mg; KI,
10 mg; Na2SeO3, 10 mg; KCr(SO4)2$12H2O, 55 mg; NaF, 6.35 mg;
and Na2SiO3$9H2O, 145 mg. The vitamin mixture (1 kg):
vitamin A (250,000 IU/g), 56.4 g; vitamin D (400,000 IU/g), 8.8 g;
vitamin E (250 IU/g), 705 g; vitamin B1, 21 g; vitamin B2, 21 g;
vitamin B6, 25 g; vitamin B12, 35mg; vitamin K, 175mg; biotin,
705 mg; folic acid, 7 g; pantothenic acid, 56 g; nicotinic acid,
106 g. The normal diet was prepared in compliance with
GB14924.3-2001 for rat formula feeds issued by the Chinese
National Institute of Standards for Laboratory Animals. The
normal diet had other materials added, such as sesame, milk
and raw eggs, thereby having more iron compared with the
low-iron diet.
2.2. Animal procedures
Six-week-old male Wistar rats breeding colony (Shanghai
SLAC Laboratory Animal Co. Ltd., Shanghai, China) were
randomly divided into nine groups of 10. Group 1 was the
control group and fed with a normal diet. Animals in Groups
2e6 were rendered anemic through low-iron diets over a
period of 5 weeks, because continued depletion of iron stores
leads to IDA and serious biological impairment [34]. The
concentration of HGB was determined every week. When the
HGB concentration was < 130 g/L, the rat model of IDA was
prepared [35]. The rats in Groups 3e6 were given different iron
supplements of 1.48 mg/kg, 2.96 mg/kg, and 14.8 mg/kg CIP,
and Ferroids containing 14.8 mg/kg iron, respectively, by
gavage. The rats in Group 2 were used as a negative control.
The HGB concentration in all rat groups was determined once
every 2 days thereafter during Groups 3e6 were treated with
the iron supplementation.The rats of groups 7e9 received a
normal diet, and Group 7 served as a control without blood
collection before dissection. Groups 8 and 9 received 100 mg/
kg and 200 mg/kg CIP orally, respectively. The animals were
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Figure 1 e Effect of different doses of oral CIP on HGB
concentration in erythrocytes of male Wistar rats. (A) Time
courses of HGB concentration of all experimental groups.
(B) HGB concentration at Day 0 and Day 8 in all
experimental groups. Group 1 was used as a control, which
was fed with normal diet. Groups 2e6 were rendered
anemic through their diet over a period of 8 weeks. Group 2
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 4 ( 2 0 1 6 ) 7 4 6e7 5 3748weighed individually on the first day, and once every 3 days
thereafter. Also, the food intake of the rats was measured
once every 3 days. Animals were killed by dislocation of cer-
vical vertebrae at the end of 13 weeks, and all animals were
fasted overnight prior to killing. All the animals were housed
in stainless steel cages and maintained in a temperature- and
light-controlled environment. The environmental conditions
were: 12-hour light/dark cycle, a temperature range of
2024C, and a relative humidity of 35e60%.
All the above experimentswere conducted according to the
guidelines issued by the institutional Animal Care Committee
and in compliance with regulations formulated by the Science
and Technology Commission of Shanghai Municipality.
2.3. Hematological and serum biochemical
determination
Venous blood samples from fossa orbitalis were drawn and
collected in 1.5-mL Eppendorf tubes coatedwith Na2-EDTA for
the measurement of the hematological parameters, using a
Sysmex XT-1800i hematology analyzer (Sysmex Medical
Electronics, Kobe, Japan), including white blood cell count,
erythrocyte count, HGB, hematocrit, mean corpuscular vol-
ume, mean corpuscular hemoglobin concentration, and
platelet count. The serum biochemical parameters included
alanine aminotransferase (ALT), glutamic oxaloacetic trans-
aminase (GOT), total protein (TP), albumin (ALB), globulin
(GLB), blood urea nitrogen, creatinine, blood glucose, triglyc-
eride and total cholesterol, which were determined by Hitachi
7150 analyzer (Tokyo, Japan).
2.4. Morphological study
Complete necropsy was performed on the treated and control
animals and organ weights of liver, kidneys, spleen and testes
were measured at the end of the study. After fixation in 10%
phosphate-buffered formalin, liver, kidneys, spleen, stomach,
ileum and testes were processed in a routine manner,
embedded in paraffin, and sectioned. Tissue sections were
examined by light microscopy after staining with hematoxy-
lin and eosin.
2.5. Statistical analysis
Experimental data were expressed as mean ± standard devi-
ation of 10 animals and were analyzed using analysis of
variance with the Scheffe multiple comparison method,
which was applied only if significant differences were deter-
mined. Differences were considered significant at p < 0.05.was used as a negative control fed with a low-iron diet
throughout the experimental period. Groups 3e6 were
given different iron supplements such as 1.48 mg/kg,
2.96 mg/kg and 14.8 mg/kg CIP and Ferroids containing
14.8 mg/kg Fe, respectively, by oral administration for 8
days. HGB concentration in all groups was determined
once every 2 days during iron supplementation. Values are
expressed as means ± standard deviation (n¼ 10). Means
for a variable not sharing a common symbol (aeg) are
significantly different (p < 0.05). CIP¼ carbonyl iron
powder; HGB¼ hemoglobin.3. Results and discussion
3.1. Effect of CIP on concentration of HGB in erythrocytes
The average HGB concentration in erythrocytes of healthy
rats (Group 1 controls) fed with normal feedstuff for 8 weeks
was 176.8 ± 7.9 g/L, while that of rats in Groups 2e6 fed an
iron-deficient diet for 8 weeks decreased to 119.3 ± 15.0 g/L.
According to Yuan et al [35], rats are considered anemicwhen the HGB level is reduced to 25% of the original level.
Groups 3e6 were fed with iron supplements, CIP at doses of
1.48 mg/kg, 2.96 mg/kg and 14.8 mg/kg and Ferroids con-
taining 14.8 mg/kg iron, and HGB concentration was deter-
mined every 2 days. Figure 1A shows the changes in HGB
concentration in erythrocytes of rats treated with different
iron supplements for 8 days. The HGB concentration in
Groups 3e5 fed with different doses of CIP increased to
18.1 g/L, 27.0 g/L and 39.4 g/L after 8 days, respectively,
which indicated a concentration-dependent curative effect.
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compared in Figure 1A. Under the condition of same dosage
of Fe, 14.8 mg/kg, the average HGB concentration increased
in Group 5 to 39.4 g/L and to 40.1 g/L in Group 6, indicating
that CIP possessed similar bioavailability as Fe2þ.
The concentration of HGB in erythrocytes in Groups 3e6
was restored to the normal level after 8 days iron supple-
mentation (Figure 1B). No significant difference was found
between Group 1 and Group 4 (p > 0.05), which meant that a
medium dose of iron supplementation (2.96 mg/kg CIP) for 8
days returned HGB level of IDA rats to normal. No significant
difference was found between Group 3 and Group 5 (p > 0.05),
which suggested that a high dose of iron supplementation
(14.8 mg/kg CIP) did not result in a continued increase in HGB
level. The above results demonstrate that a medium dose of
CIP is enough for remission from IDA, whichmight be because
of the limitation to iron absorption at high dose. When Group
5was comparedwith Group 6, whichwas fedwith Ferroids for
8 days, the average HGB concentration in erythrocytes did not
differ significantly (p > 0.05). There was no significant differ-
ence betweenGroup 3 and Group 6 (p > 0.05) or between Group
4 and Group 6 (p > 0.05). The above results show that the CIP
has a similar effect on IDA as Ferroids with the same iron
concentration. Therefore, CIP had at least the same bioavail-
ability as ferrous sulfate, and this result agrees with the
finding that CIP was reported to be more effective than
traditional iron supplements like ferrous sulfate [31]. When
some natural iron tonics, such as squid ink melanin-Fe, were
administered to IDA rats at a dose of 2 mg/kg Fe for 25 days,
the level of HGB approached normal. When heme iron at a
dose of 2mg/kg Fewas fed to IDA rats, 45 dayswere needed for
HGB level to recover to normal [36,37]. All these results suggest
that CIP can be used as an effective iron supplement.A 
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Figure 2 eMean food intake (A) and body weight (B) of male
Wistar rats (10 per group) over the course of the subchronic
90-day toxicity study of dietary carbonyl iron powder.3.2. Subchronic 90-day toxicity study
It is well established that iron can initiate hepatic lipid per-
oxidation [38]. Iron overdose results in both local and systemic
effects. Large overdoses exceed the iron-binding capacity of
transferrin, leaving free iron circulating in the plasma and
being stored in target organs [39]. Although previous acute
toxicity studies have indicated that carbonyl iron has a low
toxicity level as compared with FeSO4 and FeNa-EDTA, the
long-term effects based on toxicology are unknown [40]. Thus,
we investigated the long-term effects of orally administered
CIP at doses of 100 mg/kg and 200 mg/kg and tested for he-
matological, biochemical, morphological and histological
data.
CIP was administered by gavage at doses of 100 mg/kg and
200 mg/kg, which were based on the 50% lethal dose (> 5 g/kg
Fe) (data not shown). There were no deaths among the rats
treated with CIP during the 90-day observation period, and all
rats appeared to be healthy and normal. There were no
abnormal signs in behavior, breathing, sensory nervous sys-
tem responses, or gastrointestinal effects in the rats treated
with CIP at a dose of 200 mg/kg, which was the highest dose
that could be administered by gavage to rats. Accordingly, the
no observed adverse effect level (NOAEL) of CIP was > 200 mg/
kg. A reported NOAEL of iron sulfate was ~100 mg/kg/day in a90-day study in mice, which showed liver and spleen effects
(hemosiderosis) [41].
The food intake of the rats was monitored for 90 days
(Figure 2A). There were some differences between control
Group 7 and treated Groups 8 and 9. Such differences might
have been because large doses of CIP resulted in deposition of
iron in the stomach and reduced appetite, which led to lower
food intake. However, there was no difference between
Groups 8 and 9, even though the CIP dose differed twofold
between the groups. The body weight of the rats was also
monitored for 90 days (Figure 2B). Mean bodyweight increased
slightly on the day following treatment, and the treated
groups showed a lower average final weight than the control
group, which coincided with the food intake curve.
The hematological profiles of the control and treated
groups are presented in Table 1. Repeated oral administration
for 90 days did not cause significant changes in hematological
parameters. The serumbiochemical parameters in the 90 days
chronic toxicity study are summarized in Table 2. There was
no difference in most serum biochemical parameters among
the control and treated groups except for GOT (p < 0.05) and
GLB (p < 0.05) of Group 9. Evaluation of GOT activity is a basic
procedure for the diagnosis and monitoring of hepatocellular
disorders or muscle damage. The increase in GOT correlates
well with the extent and severity of cellular damage [42].
Table 1 e Effect of oral carbonyl iron powder on
hematological parameters in Wistar rats treated for 90
consecutive days.
Parameter Group 7 Group 8 Group 9
WBC (109/L) 12.6 ± 0.8 12.3 ± 0.8 12.2 ± 0.7
RBC (1012/L) 9.9 ± 0.4 9.9 ± 0.2 10.0 ± 0.2
HGB (g/L) 176.3 ± 2.5 177.7 ± 3.3 177.7 ± 3.1
HCT (%) 51.4 ± 1.4 51.4 ± 1.2 51.2 ± 0.8
MCV (fL) 52.4 ± 0.5 52.1 ± 0.6 52.1 ± 0.4
MCHC (g/L) 342.9 ± 3.8 344.6 ± 3.6 345.0 ± 3.5
PLT (109/L) 1021.3 ± 34.5 1028.2 ± 37.0 1037.9 ± 33.1
HCT ¼ hematocrit; HGB ¼ hemoglobin; MCHC ¼mean corpuscular
hemoglobin concentration; MCV ¼mean corpuscular volume;
PLT ¼ platelet count; RBC ¼ red blood cell count; WBC ¼white
blood cell count.
Table 2 e Effect of oral carbonyl iron powder on serum
biochemical parameters in Wistar rats treated for 90
consecutive days.
Parameter Group 7 Group 8 Group 9
ALT (U/L) 87.3 ± 10.6 76.2 ± 9.7 90.3 ± 16.3
GOT (U/L) 149.2 ± 12.2 130.8 ± 16.8 129.7 ± 25.3
TP (g/L) 69.3 ± 2.3 72.8 ± 2.2 73.3 ± 6.3
ALB (g/L) 44 ± 1.3 45.5 ± 1.5 45.5 ± 2.9
GLB (g/L) 25.3 ± 1.4 27.3 ± 1.6 27.8 ± 3.9
ALB/GLB ratio 1.75 ± 0.1 1.7 ± 0.1 1.7 ± 0.2
BUN (mmol/L) 6.7 ± 1.4 6.6 ± 0.5 6.9 ± 0.6
Cr (mmol/L) 34.8 ± 1.9 33.2 ± 1.5 34.5 ± 4.0
GLU (mmol/L) 5.2 ± 1.1 5.4 ± 0.9 6.1 ± 0.8
TG (mmol/L) 1.4 ± 0.4 1.5 ± 0.5 1.7 ± 0.3
TCH (mmol/L) 2.0 ± 0.1 2.3 ± 0.3 2.3 ± 0.3
ALB ¼ albumin; ALT ¼ alanine aminotransferase; BUN ¼ blood
urea nitrogen; Cr ¼ creatinine; GLB ¼ globulin; GLU ¼ glucose;
GOT ¼ glutamic oxaloacetic transaminase; TCH ¼ total cholesterol;
TG ¼ triglyceride; TP ¼ total protein.
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control group, which does not lead to the conclusion that CIP
damaged liver and muscle. GLB has an immune function.
Increased GLB may result from hepatocellular damage,
chronic infection, or other diseases [43]. However, GLB index is
insufficient for the diagnosis of liver diseases. So, to establishTable 3 e Effect of oral carbonyl iron powder on relative
organ weight in Wistar rats treated for 90 consecutive
days.
Parameter Group 7 Group 8 Group 9
Liver weight (g) 11.39 ± 1.00 10.74 ± 2.11 10.90 ± 1.25
Liver weight/body weight
(102)
2.42 ± 0.24 2.41 ± 0.23 2.59 ± 0.28
Kidney weight (g) 1.32 ± 0.12 1.21 ± 0.24 1.18 ± 0.13
Kidney weight/
body weight (103)
2.80 ± 0.31 2.71 ± 0.34 2.82 ± 0.18
Spleen weight (g) 0.69 ± 0.07 0.65 ± 0.10 0.58 ± 0.07
Spleen weight/
body weight (103)
1.46 ± 0.13 1.45 ± 0.2 1.38 ± 0.19
Testis weight (g) 1.76 ± 0.13 1.78 ± 0.12 1.71 ± 0.19
Testis weight/
body weight (103)
3.72 ± 0.28 3.99 ± 0.33 4.06 ± 0.34the extent of liver damage, comprehensive analysis of serum
biochemical parameters combined with data on serum ALT is
necessary.
Serum ALT concentration is one of the most commonly
used indicators for assessment of general liver health and
liver disease [33,44]. Serum ALT levels rise in disease states
that cause hepatocellular injury, therefore, serum ALT levels
can identify an ongoing liver disease process [45]. ALT levels
> 5 times the upper limit of the normal suggest a potentially
serious, active liver disease process, and ALT levels > 15
times the normal range indicate severe acute liver cell injury
[45]. The use of many drugs is associated with elevated ALT
levels, and over-the-counter medications and herbal prep-
arations are also implicated [46]. Moreover, emerging data
highlight the potential value of ALT as a measure of overall
health and survival [45]. Thus, ALT level is more important
for evaluating liver injury and overall health status.
Accordingly, we assessed differences in ALT among treated
groups and no significant differences were found (p > 0.05),
which strongly demonstrated that CIP was safe for long-
term administration.
Liver damage was induced in Wistar rats by administering
ferrous sulfate (30 mg/kg) on the 10th day, for that ALT, ALB
and TP were observed to have a surge (p < 0.01). Total
cholesterol in these rats suggested an increased risk of cere-
brovascular disease [47]. In rats treated with FeNa-EDTA, ALT
stayed almost the same, but unfortunately ALB, white blood
cell count, mean corpuscular hemoglobin concentration and
other clinical chemistry values showed significant changes
after 31 days or 61 days of feeding [48]. Therefore, the results
of serum biochemical parameters indicated that carbonyl iron
could be an effective treatment for IDA, with few side effects.
3.3. Gross pathological findings
At the end of the observation period, all rats were killed and
autopsied. All major organs including liver, kidneys, spleen,
and testes were examined grossly. No significant (p > 0.05)
differences in organ coefficient (organ weight/body weight)
among Groups 7, 8 and 9 were noted (Table 3). There were no
significant (p > 0.05) differences in organweights among these
groups (Table 3). Even feedingwith CIP up to 200mg/kg had no
adverse effects on organs. In rats fed with FeNa-EDTA, there
was some increased risk with increased dose of CIP because
there was an ~40% decrease in liver weight/body weight,
resulting in possible questions regarding hepatotrophy and
toxicity [31].
Small pieces of liver, kidneys, spleen, testes, stomach and
intestine were fixed in 10% neutral-buffered formalin, and cut
into sections that were observed under a light microscope.
Histological observations of liver, kidneys, spleen, stomach,
intestine and testes showed no treatment-related differences
compared with the control group, regardless of the dose of CIP
used (Figure 3). The texture of tissue is clear and without
typical pathological changes like inflammatory infiltration, of
treated groups compared with the control group. Several
studies have examined that different iron fortifiers such as
ferrous bisglycinate, ferrous fumarate, FeNa-EDTA, and
ferrous sulfate had varing degrees of toxic effects on certian
organs [4,31,32]. Oral ferrous fumarate and ferrous sulfate
Figure 3 e Paraffin sections of organs of male Wistar rats: (A) liver, (B) kidney, (C) spleen, (D) testis, (E) stomach, and (F)
intestine.
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j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 4 ( 2 0 1 6 ) 7 4 6e7 5 3752therapy may both reinforce intestinal inflammation under
microscopic evaluation, showing crypt loss, inflammatory
infiltration, and crypt abscesses [44]. CIP did not cause sig-
nificant organ lesions.3.4. Conclusions
CIP is a newly developed food additive or iron supplement that
has therapeutic potential for IDA, with potent bioavailability
and low toxicity based on administration and subchronic
toxicity experiments in Wistar rats. After 8 days of adminis-
tration of CIP, the HGB concentration of IDA rats returned to
normal. The results obtained from the subchronic toxicity
experiment showed no significant change in hematological,
biochemical, morphological and histological features. The
NOAEL of CIP was > 200 mg/kg. Thus, CIP has the potential to
be used as an iron supplement.Acknowledgments
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